LBCL 2022 - Year in Review

Matching-adjusted indirect comparison of liso-cel to axi-cel utilizing data from the TRANSFORM and ZUMA-7 studies revealed lower odds of key CAR-T‒associated adverse events with liso-cel. Read More ›

Phase 1 results of YTB323 in patients with R/R DLBCL demonstrate durable efficacy with a favorable safety profile, as well as identify the recommended phase 2/3 dose. Read More ›

Data from the CIBMTR registry revealed that advanced age does not impact mortality associated with CAR-T therapy, and that CAR-T therapy is feasible in older adults. Read More ›

Two distinct inflammatory clusters were identified and found to be tightly linked to response and survival of patients with LBCL receiving CAR-T therapy, with validation utilizing an independent cohort. Read More ›

Page 3 of 3

Conference Correspondent Coverage is Brought to You by the Publishers of:
Oncology Practice Management
The Oncology Nurse–APN/PA

Learn more about our family of publications.

View Our Publications